These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28763329)

  • 21. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Robotic Surgery in Patients With Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy: Survival Outcomes.
    Siesto G; Romano F; Accardi A; Bulletti C; Iedà NP; Vitobello D
    Int J Gynecol Cancer; 2016 Mar; 26(3):521-7. PubMed ID: 26825842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer.
    Choi HJ; Lee YY; Choi CH; Kim TJ; Lee JW; Bae JH; Bae DS; Kim BG
    Curr Probl Cancer; 2020 Oct; 44(5):100557. PubMed ID: 32067746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
    Chitapanarux I; Tonusin A; Sukthomya V; Charuchinda C; Pukanhapan N; Lorvidhaya V
    Gynecol Oncol; 2003 Jun; 89(3):402-7. PubMed ID: 12798702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remission of metastatic cervical adenocarcinoma with weekly paclitaxel.
    Ota S; Sugiyama T; Ushijima K; Fujiyoshi K; Komai K; Hirai N; Nishida T; Kamura T
    Int J Gynecol Cancer; 2001; 11(2):167-8. PubMed ID: 11328417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The activity of paclitaxel in gastrointestinal tumors.
    Ajani JA; Ilson DH; Kelsen DP
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):46-50; discussion 51-3. PubMed ID: 7481861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.
    Kudelka AP; Winn R; Edwards CL; Downey G; Greenberg H; Dakhil SR; Freedman RS; LoCoco S; Umbreit J; Delmore JE; Arbuck S; Loyer E; Gacrama P; Fueger R; Kavanagh JJ
    Anticancer Drugs; 1997 Aug; 8(7):657-61. PubMed ID: 9311440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer.
    Kitagawa R; Katsumata N; Ando M; Shimizu C; Fujiwara Y; Yoshikawa H; Satoh T; Nakanishi T; Ushijima K; Kamura T
    Gynecol Oncol; 2012 May; 125(2):307-11. PubMed ID: 22333993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer.
    Zanetta G; Fei F; Parma G; Balestrino M; Lissoni A; Gabriele A; Mangioni C
    Ann Oncol; 1999 Oct; 10(10):1171-4. PubMed ID: 10586332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer.
    Song D; Kong W; Zhang T; Han C; Liu T; Jiao S; Chen J
    J Obstet Gynaecol; 2019 Apr; 39(3):389-394. PubMed ID: 30663464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
    Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
    Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
    Choi HJ; Paik ES; Choi CH; Kim TJ; Lee YY; Lee JW; Bae DS; Kim BG
    Int J Gynecol Cancer; 2018 Sep; 28(7):1333-1341. PubMed ID: 30045137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
    Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
    J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study.
    Xia X; Jiang W; Qi W; Hong B; Zhao W
    Oncol Res Treat; 2020; 43(12):649-655. PubMed ID: 33045704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer.
    Yavas G; Yavas C; Sen E; Oner I; Celik C; Ata O
    Int J Gynecol Cancer; 2019 Jan; 29(1):42-47. PubMed ID: 30640682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
    Yamamoto S; Maeda N; Nagashima Y; Kubo H; Sato Y; Matsui H; Inoue Y; Shindo Y; Kanekiyo S; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yoshino S; Hazama S; Oka M; Nagano H
    Breast Cancer; 2017 Nov; 24(6):783-789. PubMed ID: 28439763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
    Nishio S; Kitagawa R; Shibata T; Yoshikawa H; Konishi I; Ushijima K; Kamura T
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):785-90. PubMed ID: 27553435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose.
    Cerrotta A; Gardan G; Cavina R; Raspagliesi F; Stefanon B; Garassino I; Musumeci R; Tana S; De Palo G
    Eur J Gynaecol Oncol; 2002; 23(2):115-9. PubMed ID: 12013105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer.
    Torfs S; Cadron I; Amant F; Leunen K; Berteloot P; Vergote I
    Eur J Cancer; 2012 Jun; 48(9):1332-40. PubMed ID: 22317951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.